A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1708 in Healthy Japanese Participants
Latest Information Update: 27 Aug 2024
At a glance
- Drugs MK 1708 (Primary)
- Indications Alzheimer's disease; Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms MK-1708-004
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 27 Aug 2024 New trial record